AbbVie Needs To Freshen Up

 
• By Elizabeth Cairns and Edwin Elmhirst
  
Generate a summary of this article
Listen to this article
Beta

With half of its 2023 sales coming from aging blockbusters like Humira and Botox, AbbVie needs new blood.    

Economic recovery and growing wealth business metaphor as a group of trees shaped as a dollar sign growing leaves and bearing fruit as a symbol of wealth and financial success in a growth industry.

Big pharma companies must constantly reinvent themselves if they are to ensure their revenues grow, developing new therapies to replace the older drugs whose patents are approaching expiry. AbbVie Inc. in particular needs to accelerate this process: nearly half of its revenues last year came from products that are more than 15 years old.

Key Takeaways

  • AbbVie, Sanofi and Merck & Co get a large proportion of their sales from older drugs, potentially imperiling their future growth

Several other groups could also do with zhuzhing up their offerings. Around 40% of the 2023 sales of Sanofi...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Business

Test Roche Head Of Pharma Strategy Karsten Jung On Rebuilding The Portfolio

 
• By Jessica Merrill

The Swiss pharma company is rebalancing the portfolio, emphasizing best-in-class drugs and moving into new areas like cardiovascular and metabolic disease.

Quick Listen: Scrip’s Five Must-Know Things

 
• By Reed Miller

In this week's episode: Trump’s UK drug pricing win; Novo explains semaglutide Alzheimer's rationale; J&J and Novartis on this year’s biggest M&A deals; a look at the mixed performance of CAR-Ts; and Akeso’s goals beyond ivonescimab.

Article Without An Author Listed

Here is a short description.

Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]

Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.

More from Scrip

EHA: Lilly’s Jaypirca Posts First Phase III Triplet Win In CLL While BTK Degraders Advance

Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.

EHA: Lilly’s Jaypirca Posts First Phase III Triplet Win In CLL While BTK Degraders Advance - Clone

Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.